Program Status
RecruitingPhase
Phase 1 Phase 2Prior Immunotherapy Allowed
YesCRC-directed Trial
YesDrugs
AFNT-211Tags
MSI-H/ MMRd, MSS/ MMRpComments
Targeted immunotherapy-only trial that admits patients with advanced/ metastatic colorectal cancer with a KRAS G12V mutation. For both, MSS and MSI-H patients.
Trial with engineered TCR T-cells.
AFNT-211: cellular therapy; autologous CD4+ and CD8+ T cells engineered to express a HLA-A*11:01-restricted KRAS G12V-specific transgenic T cell receptor (TCR), the wildtype CD8α/β coreceptor, and a FAS-41BB switch receptor (see Helpful Links for Publications).
Prior immunotherapy allowed, as well as other therapies, after a 14 days wash-out period.
No need to exhaust standard of care: patients are allowed if they progressed on or are intolerant of at least one prior line of standard systemic
| Location | Location Status |
|---|---|
| United States | |
|
USC Norris Comprehensive Los Angeles, California 90033 |
Recruiting |
|
University of California Los Angeles Department of Medicine Los Angeles, California 90095 |
Recruiting |
|
University of California San Francisco San Francisco, California 94143 |
Recruiting |
|
Yale New Haven Hospital New Haven, Connecticut 06511 |
Recruiting |
|
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health New York, New York 10016 |
Recruiting |
|
Memorial Sloan Kettering Cancer Center New York, New York 10065 |
Recruiting |
|
Providence Cancer Institute Franz Clinic Portland, Oregon 97213 |
Recruiting |
|
Sarah Cannon Research Institute Nashville, Tennessee 37203 |
Recruiting |
|
MD Anderson Cancer Center Houston, Texas 77030 |
Recruiting |
|
Fred Hutchinson Cancer Center Seattle, Washington 98109 |
Recruiting |
|
University of Wisconsin Carbone Cancer Center Madison, Wisconsin 53792 |
Recruiting |
Contacts
Inclusion Criteria
Key Inclusion Criteria:
1. Confirmed KRAS G12V mutational status and HLA-A*11:01 allele
2. Histologically confirmed advanced or metastatic, unresectable solid tumor
3. Progressed on or intolerant of at least one prior line of standard systemic therapy for the current malignancy.
4. Measurable disease per RECIST v1.1.
5. ECOG performance status 0-1
6. Adequate organ and bone marrow function
Key
Exclusion Criteria
Exclusion Criteria:
1. Any systemic cytotoxic chemotherapy, investigational agents, or any anti-tumor drug from a previous treatment regimen or clinical study (including small molecules and I/O compounds) within 5 half-lives or 14 days of Screening, whichever is shorter.
2. Any prior gene therapy utilizing an integrating vector
3. Previous allogeneic stem cell transplantation or prior organ transplantation
4. History of treated primary immunodeficiency, autoimmune, or inflammatory disease including inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, or Grave's disease
5. Primary brain tumor
6. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression.
7. Uncontrolled active bacterial, viral, fungal, or mycobacterial infection
8. Pregnant or lactating subjects
9. Surgery or catheter-based interventions
10. Previously identified allergy, hypersensitivity, or known contraindication to cyclophosphamide, fludarabine, or any other agent associated with lymphodepleting chemotherapy (LDC) or AFNT-211 product
11. Uncontrolled significant intercurrent or recent illness
12. Diagnosis of another malignancy within 2 years prior to screening.
13. Seropositive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb)
14. Seropositive for hepatitis C antibody.
15. Known human immunodeficiency virus (HIV) infection
